Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression

Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression

Leprosy remains a health problem in several countries. Current management of patients with leprosy is complex and requires multidrug therapy. Nonetheless, antibiotic treatment is insufficient to prevent nerve disabilities and control Mycobacterium leprae. Successful infectious disease treatment dema...

Full description

Bibliographic Details
Main Authors:	Hayana Ramos Lima, Thaís Helena Gasparoto, Tatiana Salles de Souza Malaspina, Vinícius Rizzo Marques, Marina Jurado Vicente, Elaine Camarinha Marcos, Fabiana Corvolo Souza, Maria Renata Sales Nogueira, Jaison Antônio Barreto, Gustavo Pompermaier Garlet, João Santana da Silva, Vânia Nieto Brito-de-Souza, Ana Paula Campanelli
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-12-01
Series:	Frontiers in Immunology
Subjects:	immunotherapy leprosy T-regulatory cells immune checkpoint blockade PD-1:PD-L1 cytotoxic T-lymphocyte-associated protein 4
Online Access:	http://journal.frontiersin.org/article/10.3389/fimmu.2017.01724/full

Similar Items

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
by: Jan Willem Kleinovink, et al.
Published: (2017-04-01)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
by: Eric Bartee, et al.
Published: (2017-05-01)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020-08-01)

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura
by: James T. Boothe, et al.
Published: (2017-11-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
by: Maria Georganaki, et al.
Published: (2018-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
by: Zachary S. Buchwald, et al.
Published: (2018-12-01)

Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01)

Inhibition of immune checkpoints and Vascular Endothelial Growth Factor as combination therapy for cancer: an overview of rationale, preclinical evidence, and initial clinical data
by: Patrick Alexander Ott, et al.
Published: (2015-09-01)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
by: Giandomenico Roviello, et al.
Published: (2021-08-01)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
by: Xi Chen, et al.
Published: (2020-05-01)

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
by: Zin W. Myint, et al.
Published: (2017-04-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
by: Junyu Long, et al.
Published: (2017-08-01)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
by: Jessica M. Konen, et al.
Published: (2019-04-01)

Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
by: Vida Vafaizadeh, et al.
Published: (2020-03-01)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
by: Kripa Guram, et al.
Published: (2019-03-01)

Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01)

Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer
by: Ivan Shevchenko, et al.
Published: (2018-08-01)

Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs
by: Stanislav Pantelyushin, et al.
Published: (2021-02-01)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Pierpaolo Correale, et al.
Published: (2020-08-01)

Basis for Immunotherapy for Treatment of Meningiomas
by: Tomas Garzon-Muvdi, et al.
Published: (2020-08-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

Recent advances and application of PD-1 blockade in sarcoma
by: Zuo W, et al.
Published: (2019-08-01)

Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia
by: Jie Gao, et al.
Published: (2019-09-01)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
by: Jan Willem Kleinovink, et al.
Published: (2017-07-01)

Assessment of tumor mutation burden calculation from gene panel sequencing data
by: Xu Z, et al.
Published: (2019-05-01)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
by: Yiting Sun, et al.
Published: (2021-08-01)

Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01)

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
by: Fei Tang, et al.
Published: (2018-05-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
by: Qi X, et al.
Published: (2017-12-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
by: Yan Lin, et al.
Published: (2020-01-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature
by: Elizabeth McGehee, et al.
Published: (2021-04-01)

Response: Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
by: Yan Lin, et al.
Published: (2020-07-01)